新一代抗癌药物与颌骨药物相关性骨坏死（MRONJ）：在静脉注射伊匹单抗3年后出现迟发性发病，靶向治疗可能起作用。
New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
作者信息
Guida Agostino, Perri Francesco, Ionna Franco, Ascierto Paolo A, Grimaldi Antonio M
机构信息
Maxillo-facial and ENT Surgery Unit INT - IRCCS "Fondazione G. Pascale" Naples Italy.
Head & Neck/Thyroid Medical Oncology Unit INT - IRCCS "Fondazione G. Pascale" Naples Italy.
出版信息
Clin Case Rep. 2020 Dec 2;9(1):61-66. doi: 10.1002/ccr3.3418. eCollection 2021 Jan.
Abstract
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.
摘要
免疫疗法和/或化疗和/或靶向疗法按顺序或作为单一疗法联合使用，可能会诱发颌骨坏死。应对这些患者进行多学科团队管理。
Zotero 插件